2018
DOI: 10.6061/clinics/2018/e430s
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: In the current context of epidemiological transition, demographic changes, changes in consumption and lifestyle habits, and pressure on care costs and organized health systems for acute conditions, the Integrated Care Model by Shortell has become a conceptual reference in the search for new methods to manage chronic conditions by focusing on the health conditions of a given population that must be addressed by a set of institutions organized into networks. Within the last 15 years, cancer has gone from the thi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 2 publications
(2 reference statements)
0
1
0
Order By: Relevance
“…The MoH is responsible for the oncological network and financial policy established. The centers denominated High-Complexity Oncology Centers (CACON) and High-Complexity Oncology Units (UNACON) are responsible for comprehensive care, including patient's access to oncological medicines 59 . Besides legislation creating comprehensive insurance systems, a study by Barrios and Werutsky 60 highlights that access to innovative oncological HPMs is low in Brazil and, in general, is lagging many years behind concerning the date approval in developed countries.…”
Section: Policies For Oncological Medicinesmentioning
confidence: 99%
“…The MoH is responsible for the oncological network and financial policy established. The centers denominated High-Complexity Oncology Centers (CACON) and High-Complexity Oncology Units (UNACON) are responsible for comprehensive care, including patient's access to oncological medicines 59 . Besides legislation creating comprehensive insurance systems, a study by Barrios and Werutsky 60 highlights that access to innovative oncological HPMs is low in Brazil and, in general, is lagging many years behind concerning the date approval in developed countries.…”
Section: Policies For Oncological Medicinesmentioning
confidence: 99%